Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 19/20 | 0.41 |
| ▸ | CA1 | P00915 | 18/20 | 0.41 |
| ▸ | CA9 | Q16790 | 16/20 | 0.41 |
| ▸ | CA12 | O43570 | 12/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 10/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | CA5A | P35218 | 1/20 | 0.35 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5733048 | 0.90 | CA2 (0.41) | CA2CA1CA9CA12CA14 | |
| SCHEMBL5732778 | 0.89 | LNPEP (0.37) | — | |
| SCHEMBL5732942 | 0.88 | CA2 (0.43) | CA2CA1CA9CA12CA14 | |
| SCHEMBL9030782 | 0.80 | TBXAS1 (0.41) | — | |
| SCHEMBL8146329 | 0.79 | CTSK (0.47) | — | |
| SCHEMBL5732085 | 0.78 | CA2 (0.43) | CA2CA1CA9CA12CA14 | |
| SCHEMBL5732592 | 0.77 | LNPEP (0.38) | — | |
| SCHEMBL5733045 | 0.73 | DRD1 (0.40) | CA2CA1CA9CA12CA14 | |
| SCHEMBL8558001 | 0.70 | CTSA (0.41) | CA2CA1CA9CA12CA4 | |
| SCHEMBL5732083 | 0.68 | KMT2A (0.41) | CA2CA1CA9CA12CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060251689-A1 | Treatment or prevention of pruritus | ASTION DEVELOPMENT A/S | 2006-11-09 | — | — | US | claimed |
| US-20060229347-A1 | Treatment of eczemas | ASTION DEVELOPMENT A/S | 2006-10-12 | — | — | US | claimed |
| WO-2006102899-A2 | OXAPROZIN OR CLOSELY RELATED COMPOUND FOR THE TREATMENT AND PREVENTION OF | ASTION PHARMA A/S (DK) | 2006-10-05 | — | — | WO | claimed |
| WO-2006102898-A2 | OXAPROZIN OR A CLOSELY RELATED COMPOUND FOR THE TREATMENT OF ECZEMA | ASTION PHARMA A/S (DK) | 2006-10-05 | — | — | WO | claimed |
| WO-2006102900-A1 | DERMATOLOGICAL COMPOSITIONS AND SALTS FOR THE TREATMENT OF DERMATOLOGICAL DISEASES | ASTION PHARMA A/S (DK) | 2006-10-05 | — | — | WO | claimed |
| US-20060222671-A1 | Dermatological compositions and salts for the treatment of dermatological diseases | ASTION DEVELOPMENT A/S | 2006-10-05 | — | — | US | claimed |
| EP-1707200-A1 | Dermatological compositions comprising oxaprozin or a closely related compound for the treatment of dermatological diseases | Astion Development A/S (DK) | 2006-10-04 | — | — | EP | claimed |
| EP-1707199-A1 | Oxaprozin or closely related compound for the treatment and prevention of pruritus | Astion Development A/S (DK) | 2006-10-04 | — | — | EP | claimed |
| EP-1707201-A1 | Oxaprozin or a closely related compound for the treatment of eczema | Astion Development A/S (DK) | 2006-10-04 | — | — | EP | claimed |
| US-20060251689-A1 | Treatment or prevention of pruritus | ASTION DEVELOPMENT A/S | 2006-11-09 | — | — | US | disclosed |
| US-20060229347-A1 | Treatment of eczemas | ASTION DEVELOPMENT A/S | 2006-10-12 | — | — | US | disclosed |
| WO-2006102899-A2 | OXAPROZIN OR CLOSELY RELATED COMPOUND FOR THE TREATMENT AND PREVENTION OF | ASTION PHARMA A/S (DK) | 2006-10-05 | — | — | WO | disclosed |
| WO-2006102898-A2 | OXAPROZIN OR A CLOSELY RELATED COMPOUND FOR THE TREATMENT OF ECZEMA | ASTION PHARMA A/S (DK) | 2006-10-05 | — | — | WO | disclosed |
| WO-2006102900-A1 | DERMATOLOGICAL COMPOSITIONS AND SALTS FOR THE TREATMENT OF DERMATOLOGICAL DISEASES | ASTION PHARMA A/S (DK) | 2006-10-05 | — | — | WO | disclosed |
| US-20060222671-A1 | Dermatological compositions and salts for the treatment of dermatological diseases | ASTION DEVELOPMENT A/S | 2006-10-05 | — | — | US | disclosed |
| EP-1707200-A1 | Dermatological compositions comprising oxaprozin or a closely related compound for the treatment of dermatological diseases | Astion Development A/S (DK) | 2006-10-04 | — | — | EP | disclosed |
| EP-1707201-A1 | Oxaprozin or a closely related compound for the treatment of eczema | Astion Development A/S (DK) | 2006-10-04 | — | — | EP | disclosed |
| US-6090834-A | ANALGESICS; RHEUMATIC DISORDERS; SKIN DISORDERS; GASTROINTESTINAL DISORDERS | G.D. SEARLE & CO. (US) | 2000-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229347-A1 | Treatment of eczemas | ZAP70, SYK, LCK | CA2 1141/4885CA1 3406/4885CA9 3449/4885 |
| US-20060251689-A1 | Treatment or prevention of pruritus | ITCH, TSLP, HRH4 | CA2 329/4885CA1 1343/4885CA9 2296/4885 |
| US-20060222671-A1 | Dermatological compositions and salts for the treatment of dermatological diseases | ZAP70, SYK, LCK | CA2 750/4885CA1 2630/4885CA9 3494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.